Evidence map›Paper›PMID 24587342›Full record

ArticlePloS one2014

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells.

Aradhana Rani, Roseanna Greenlaw, Manohursingh Runglall, Stipo Jurcevic, Susan John

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Aradhana RaniDivision of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom.
Roseanna GreenlawDivision of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom.
Manohursingh RunglallDivision of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom.
Stipo JurcevicDivision of Transplantation Immunology and Mucosal Biology, King's College London, London, United Kingdom.
Susan JohnDepartment of Immunobiology, King's College London, London, United Kingdom.
King's College London · GBInnate Pharma (France) · FR

Funding

British Heart Foundation PG/09/080/28014Medical Research Council G0400197Medical Research Council MR/J006742/1Wellcome TrustWellcome Trust 074656/Z/04/Z
6 · The paper itself

Abstract

Signal transducers and activators of transcription 5(STAT5) are cytokine induced signaling proteins, which regulate key immunological processes, such as tolerance induction, maintenance of homeostasis, and CD4 T-effector cell differentiation. In this study, transcriptional targets of STAT5 in CD4 T cells were studied by Chromatin Immunoprecipitation (ChIP). Genomic mapping of the sites cloned and identified in this study revealed the striking observation that the majority of STAT5-binding sites mapped to intergenic (>50 kb upstream) or intronic, rather than promoter proximal regions. Of the 105 STAT5 responsive binding sites identified, 94% contained the canonical (IFN-γ activation site) GAS motifs. A number of putative target genes identified here are associated with tumor biology. Here, we identified Fos-related antigen 2 (FRA2) as a transcriptional target of IL-2 regulated STAT5. FRA2 is a basic -leucine zipper (bZIP) motif 'Fos' family transcription factor that is part of the AP-1 transcription factor complex and is also known to play a critical role in the progression of human tumours and more recently as a determinant of T cell plasticity. The binding site mapped to an internal intron within the FRA2 gene. The epigenetic architecture of FRA2, characterizes a transcriptionally active promoter as indicated by enrichment for histone methylation marks H3K4me1, H3K4me2, H3K4me3, and transcription/elongation associated marks H2BK5me1 and H4K20me1. FRA2 is regulated by IL-2 in activated CD4 T cells. Consistently, STAT5 bound to GAS sequence in the internal intron of FRA2 and reporter gene assays confirmed IL-2 induced STAT5 binding and transcriptional activation. Furthermore, addition of JAK3 inhibitor (R333) or Daclizumab inhibited the induction in TCR stimulated cells. Taken together, our data suggest that FRA2 is a novel STAT5 target gene, regulated by IL-2 in activated CD4 T cells.

Indexed as

Antibodies, Monoclonal, HumanizedBase SequenceBinding SitesCD4-Positive T-LymphocytesDaclizumabDNA, IntergenicEpigenesis, GeneticFos-Related Antigen-2Gene Expression RegulationGenes, ReporterHEK293 CellsHistonesHumansImmunoglobulin GInterleukin-2IntronsAntibodies, Monoclonal, HumanizedDaclizumabDNA, IntergenicFOSL2 protein, humanFos-Related Antigen-2HistonesImmunoglobulin GInterleukin-2JAK3 protein, humanJanus Kinase 3LuciferasesSTAT5 Transcription Factor

Identifiers

PMID24587342
PMCPMC3938719
OpenAlexW2010986500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.